Search research articles
Contact Us
Filters
Showing results (61-70 of 76) with videos related to
Page
of 8
Sort By:
European Journal of Haematology
|
November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Ruben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
British Journal of Haematology
|
July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N Harrison, Martin Griesshammer, Carole Miller, et al.
Clinical Epigenetics
|
August 22, 2021
DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A<sub>2</sub> in human vulnerable atherosclerotic plaque
Jingjin Li, Xiaoping Zhang, Mengxi Yang, et al.
The New England Journal of Medicine
|
January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer
Nicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
The Oncologist
|
May 4, 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hani Babiker, Irene Brana, Daruka Mahadevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
The Lancet. Haematology
|
April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 76) with videos related to
Sort By:
Page
of 8
European Journal of Haematology
|
November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
Ruben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
British Journal of Haematology
|
July 10, 2018
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Claire N Harrison, Martin Griesshammer, Carole Miller, et al.
Clinical Epigenetics
|
August 22, 2021
DNA methylome profiling reveals epigenetic regulation of lipoprotein-associated phospholipase A<sub>2</sub> in human vulnerable atherosclerotic plaque
Jingjin Li, Xiaoping Zhang, Mengxi Yang, et al.
The New England Journal of Medicine
|
January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia vera
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2012
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer
Nicoletta Colombo, Elzbieta Kutarska, Meletios Dimopoulos, et al.
The Oncologist
|
May 4, 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hani Babiker, Irene Brana, Daruka Mahadevan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
The Lancet. Haematology
|
April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Page
of 8